Forbes does not accept payment for placement on lists.

From the Editor
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and gro... Read More
Ipsen Company Stats
Industry
Drugs & Biotechnology
Founded
1929
Headquarters
Paris
Country/Territory
France
Chief Executive Officer
David G. Loew
Employees
5,000

Forbes Lists

#1946

Ipsen Financial Summary

Select list year
2024
2023
Revenue
$3.4B
Assets
$7B
Profits
$696.7M
Sources
FactSet, Bloomberg, S&P Cap IQ; Forbes.
Related People & Companies
Henri Beaufour
Henri Beaufour
Company Stakeholder
View Profile
Bartell Drugs
Bartell Drugs
Related by Industry: Drugs & Biotechnology
View Profile
HEC Paris
HEC Paris
Located in France
View Profile

More on Forbes